Foundations, promises and uncertainties of personalized medicine
- 1 April 2007
- journal article
- review article
- Published by Wiley in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Vol. 74 (1), 15-21
- https://doi.org/10.1002/msj.20005
Abstract
Personalized medicine introduces the promise to use molecular markers that signal the risk of disease or its presence before clinical signs and symptoms appear. This information underlies a new healthcare strategy focused on prevention and early intervention, rather than reaction to advanced stages of disease. Such a strategy can delay disease onset or minimize symptom severity. The molecular foundations that enable personalized medicine include detection of variation in nucleotide sequence of genes and in characteristic patterns of gene expression, proteins and metabolites. Genetic and molecular patterns are correlated with disease manifestations, drug responses, treatment prognosis, or prediction of predisposition to future disease states. However, the uncertainties for personalized medicine are considerable, including economic, ethical, legal, and societal questions. Although much of its promise remains unproven to date, the foundations of personalized medicine appear solid and evidence is accumulating rapidly pointing to its growing importance in healthcare (Fig. 1). Mt Sinai J Med 74:15–21, 2007. © 2007 Mount Sinai School of MedicineKeywords
This publication has 25 references indexed in Scilit:
- Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directionsOncogene, 2006
- An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data setsNature Genetics, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based SampleJNCI Journal of the National Cancer Institute, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseThe New England Journal of Medicine, 2005
- ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapyPharmacogenetics and Genomics, 2005
- Whole-Genome Patterns of Common DNA Variation in Three Human PopulationsScience, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- The International HapMap ProjectNature, 2003
- Genetic dissection of complex traits: guidelines for interpreting and reporting linkage resultsNature Genetics, 1995